NCT07569900 A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test
| NCT ID | NCT07569900 |
| Status | Recruiting |
| Phase | — |
| Sponsor | bioLytical Laboratories |
| Condition | Gonorrhea Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 650 participants |
| Start Date | 2025-11-26 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 650 participants in total. It began in 2025-11-26 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to evaluate the performance, usability, and contrived result interpretation of iStatis Gonorrhea Antigen Test (iStatis Gonorrhea Test) in the intended near-patient or point-of-care setting by trained personnel.
Eligibility Criteria
Inclusion Criteria * Age \> 16 years * Subject (or legally authorized representative) is willing to provide written informed consent before any study procedures * Female gender * Subject is able and willing to provide vaginal swab specimen for study procedures (3-4 swabs) * Subject can complete the required testing on the allocated testing day * Subject can speak, read, and write English * Subject's demographic information, risk factors, and symptoms are available and can be recorded on case report forms * Subject agrees to comply with study procedures and sample collection for both the investigational device and the reference method * Subject is willing to participate in the study site's standard-of-care Gonorrhea counselling and testing program and receive standard-of-care test results, as required and applicable * Subject is indicated for sexually transmitted infection testing for one or more of the following reasons: * At risk of Gonorrhea, such as recent unprotected intercourse, multiple or new partners within \< 60 days, known exposure to an infected partner, or prior STI history * Having signs and/or symptoms suggestive of Gonorrhea (e.g., urethral, vaginal, rectal, or pharyngeal discharge; dysuria; pelvic or lower-abdominal pain; sore throat; or rectal discomfort) * Undergoing routine or opportunistic STI screening, including family-planning, antenatal, or sexual-health clinic visits * Undergoing re-testing (test-of-cure) \> 7 days after completion of Gonorrhea treatment and clinically stable * Undergoing co-testing for other STIs where Gonorrhea testing is part of a broader diagnostic panel Exclusion Criteria * Subject 15 years of age or younger * Male gender * Female currently menstruating * Subject is unable or unwilling to provide informed consent * Subject is medically unstable or has psychiatric condition(s) that pose a risk or prevent study compliance * Subject is unable to provide paired samples for reference testing * Subject requires urgent antimicrobial treatment before specimen collection * Subject received systemic or topical antibiotics active against Gonorrhea within the previous 7 days * Subject used topical intravaginal or rectal antiseptics within 48 hours prior to study sampling * Previously enrolled for the same infection episode * Anatomical or clinical contraindication to study sampling (e.g., severe cervical pathology) * Recent urogenital procedure (e.g., cystoscopy, lavage) \< 72 hours before study sampling * Subject belongs to a protected group excluded by local ethics (e.g., incarcerated persons), unless explicitly approved by the EC/IRB * Any condition that, in the opinion of trained personnel or study staff, would make the participant unsuitable or unsafe for enrolment, interfere with completion of assessments, consent, or questionnaires, or bias study outcomes * Subject is participating in another interventional clinical study within 30 days that could interfere with study results
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07569900 clinical trial?
This trial is open to female participants only, aged 16 Years or older, studying Gonorrhea Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07569900 currently recruiting?
Yes, NCT07569900 is actively recruiting participants. Contact the research team at asubramanian@biolytical.com for enrollment information.
Where is the NCT07569900 trial being conducted?
This trial is being conducted at Johannesburg, South Africa, Durban, South Africa, Cape Town, South Africa.
Who is sponsoring the NCT07569900 clinical trial?
NCT07569900 is sponsored by bioLytical Laboratories. The trial plans to enroll 650 participants.